We identified a somatic mutation in estrogen receptor-a (ERa) in breast cancer causing a lysine to arginine transition (K303R) resulting in hypersensitivity to estrogen, altered associations with coactivators and corepressors and altered posttranslational modifications of ERa. We have developed a transgenic mouse expressing the K303R mutant ERa under control of the mouse mammary tumor virus (MMTV) promoter. At 4 months of age, K303R ERa transgenic animals demonstrate precocious alveolar budding compared with wild-type ERa transgenic mice or nontransgenic littermates. Despite these morphologic differences, K303R ERa transgenic mice displayed no differences in levels of ERa, progesterone receptor or proliferation at this time-point. Pregnancy or chronic estrogen plus progesterone exposure in K303R ERa transgenic mice also resulted in significantly more alveolar budding, increased b-casein production and dilated ducts when compared with nontransgenic littermates. To examine the effects of mutant expression on tumorigenesis, mutant ERa mice were crossed with FVB-MMTVneu mice and significantly delayed time to neu-mediated tumorigenesis in bigenic animals. In contrast, mutant expression did not affect carcinogen-induced tumorigenesis. Collectively, these data demonstrate that aberrant estrogenic signaling through the K303R ERa mutation may lead to precocious alveolar budding in virgin mice, and to an expedited maturation and differentiation phenotype in the mammary glands of hormonally stimulated animals.
Introduction
Estrogen receptor-a (ER-a) is a central player in both normal mammary development and breast tumor progression. Work with ERa knockout mice has demonstrated an important role for ERa in ductal elongation during normal mammary gland development (Bocchinfuso and Korach, 1997) . Conversely, it is well accepted that aberrant ERa signaling plays a role in human breast cancer progression because the majority of breast cancers express ERa. Genetic factors such as somatic mutations, and epigenetic factors such as phosphorylation and acetylation, are known to alter the normal functions of ERa resulting in aberrant receptor signaling.
Recent publications analysing conditional overexpression of ERa have suggested a role for ERa in the progression of preneoplastic mammary lesions in mammary tumors in mice. Frech et al. (2005) have reported that 95% of mice conditionally overexpressing wild-type (WT) ERa displayed abnormal ductal structures by 4 months of age. Additionally, when these 4-month-old virgin mice were analysed, lobular and ductal hyperplasias were found in 52 and 36% of the mice, respectively, with a small percentage of animals displaying ductal carcinoma in situ (DCIS; Frech et al., 2005) . Treating these animals with high concentrations of estrogen did not alter the incidence of hyperplasias or DCIS (Frech et al., 2005) . Tilli et al. (2003) have reported that by 11 months of age, the conditional overexpression of T-antigen-ERa resulted in adenocarcinomas in 37% of the animals analysed. It was also noted that the exogenously expressed ERa transgene was not physiologically downregulated like endogenous receptor following estrogen stimulation, which might have contributed to the pathogenesis in their system (Frech et al., 2005) . These results suggest that altered ERa signaling may play a role in preneoplastic changes contributing to mammary tumorigenesis in mice.
In human breast cancer, retention of ERa expression is typically associated with good prognosis, and these tumors tend to be hormone-dependent, and respond to antiestrogen treatments. A number of mutations have been identified in ERa with various functional consequences to the protein (for a complete review see Herynk and Fuqua, 2004) . However, only the somatic K303R ERa mutation has been identified in more than one or two patients. We originally identified this mutation in 34% of breast hyperplasias (Fuqua et al., 2000) , and have since expanded our studies to a larger cohort of untreated breast cancer patients (Herynk et al., 2007) . In that study, we demonstrated a K303R mutation frequency of 50% in invasive cancers (both ERa-positive and -negative tumors), with a predominance of the mutation in older patients (>50 years of age), and significant associations with larger tumor size and positive lymph node status. It is known that larger tumor size and positive lymph node status are associated with poor prognosis in breast cancer. Indeed, we found significant associations of the mutation with poor prognosis in univariate analyses. Using a different detection method, Conway et al. (2005) could detect the K303R ERa mutation in 6% of the breast cancers tested. A number of groups (Tokunaga et al., 2004; Davies et al., 2005) have failed to identify this mutation in patient samples. We have reported that detection methods may account for these differences in detection rates; comparing automated sequencing vs primer extension sequence analysis, we identified primer extension as the most sensitive method for detection of this mutant (Herynk et al., 2007) . Although the actual frequency of the mutation thus remains to be clearly defined, it is apparent that it is present in a proportion of invasive breast cancers, and is the most frequent ERa mutation yet reported.
The functional consequences of the K303R ERa mutation in breast cancer cell lines have been reported in a number of papers both from our lab and others'. We originally found MCF-7 human breast cancer cells coexpressing endogenous WT receptor and the K303R ERa mutation to be hypersensitive to low levels of estrogen, even in the presence of the endogenous receptor (Fuqua et al., 2000) . Additionally, the mutant receptor demonstrated increased binding to the ERa coactivator SRC-2/TIF-2 (Fuqua et al., 2000) . Conversely, although the ER corepressor MTA2 suppresses the transcriptional activity of WT ERa (Mishra et al., 2003) , the K303R mutant receptor was not repressed by MTA2 (Cui et al., 2006) . ERa is known to be posttranslationally modified by events such as phosphorylation, protein acetylation and sumoylation, to name a few (Wang et al., 2001; Herynk and Fuqua, 2004; Sentis et al., 2005) . The mutation alters ERa regulation by allowing ER to be more highly phosphorylated by protein kinase-A as well as removing a key acetylation site on ERa (Cui et al., 2004) . These modifications render the receptor hypersensitive to growth factor and estrogen signaling. Given these data, it is clear that the K303R ERa mutation can have important effects on posttranslational modifications of ERa, and hence, on the receptor's potential signaling and subsequent functional consequences.
In this paper, we report that expression of the K303R ERa mutation in virgin transgenic (Tsg) mice led to altered hormone responsiveness and enhanced mammary alveolar morphogenesis at high frequency. Chronic hormonal stimulation using pituitary isografts resulted in increased alveolar budding, the formation of large dilated ducts and altered lipid secretion in mutantexpressing mice, which suggests expedited maturation and differentiation of mammary glands in the K303R ERa Tsg mice. Additionally, crossing the K303R ERa Tsg mice with MMTVneu-expressing mice led to a significant delay in the appearance of mammary tumors. These results demonstrate that expression of the K303R ERa mutant significantly affects the normal functions of ERa, thereby influencing the early development and hormonal response of the mammary gland.
Results

Generation of K303R ERa transgenic mice
The K303R mutant and the WT ERa cDNAs were placed under the control of the mouse mammary tumor virus (MMTV) promoter to direct expression of the transgene selectively to the mammary gland ( Figure 1a) . Founder lines were identified by Southern blot analysis; the mutant K303R ERa founder is shown in Figure 1b (lane no. 4), and the WT ERa founder animal is shown in Figure 1c (lane no. 5). Subsequent animals were tested for transgene presence by genomic PCR specific for the HA-containing tagged ERa sequence, and thyroid stimulating hormone-b (TSH-b) as a positive control (Lavrovsky et al., 1998) . Examples of positive and negative animals are shown in Figure 1d .
To confirm RNA expression of the transgene, mRNA was purified from mammary glands, reverse transcribed, PCR amplified and analysed by SNaPshot mutation analysis, because we have previously shown that this method was most sensitive for mutation detection of the K303R (A908G) ERa mutation (Herynk et al., 2007) . The primers used to amplify the cDNA products were designed to amplify only the exogenous human ERa transgene and not the endogenous mouse ERa sequence. A C57/Bl6 breeder control mouse and three non-Tsg mice did not show a human-specific ERa band, whereas the two Tsg animals showed cDNA amplification (as previously determined by DNA sequencing (Figure 1e ). SNaPshot analysis of cDNA was also performed to verify the K303R ERa mutant status and expression of the transgene in K303R ERa mutant Tsg animals (Herynk et al., 2007; data not shown) .
Mammary gland development in virgin mice
Mammary glands from K303R or WT ERa, and nonTsg virgin mice were examined at 5 weeks, 2 months and 4 months postpartum to look for structural differences. Five-week-old mice from all groups (non-Tsg n ¼ 5 and K303R ERa Tsg n ¼ 5) demonstrated normal structural features (not shown). The mammary fatpad was approximately 40-60% filled in each mouse with similar numbers of growing endbuds. At 2 months of age, the mammary fatpad was completely filled with very little evidence of lateral budding, and no differences were observed between K303R ERa Tsg (n ¼ 5) and non-Tsg (n ¼ 5) animals (data not shown). By 4 months of age, however, mammary glands from K303R ERa-expressing mice (Figure 2A , panels e and f, arrows) demonstrated more budding when compared with non-Tsg ( Figure 2A , panels a and b) and WT ERa-expressing animals ( Figure 2A , panels c and d). Sixty-five percent (9/14) of the 4-month-old Tsg mice displayed increased budding, whereas none of the non-Tsg mice (0/5) or 12% (1/6) of the WT ERa-expressing mice (Po0.05, Fisher exact test). When the animals had reached 6 months of age, lateral budding of non-Tsg (n ¼ 8) and WT ERa (n ¼ 5) Tsg mice was equal to that of the K303R ERa (n ¼ 13) Tsg mice, and all groups displayed similar morphology. Mammary glands from older animals (12 months and >18 months) showed no overt differences. Collectively, these results demonstrate that Tsg mice expressing the K303R ERa mutant exhibit precocious budding compared with WT ERa or nonTsg mice.
Virgin mammary glands were analysed by standard hematoxylin and eosin (H&E) staining, for the expression of ERa and progesterone receptor (PR) by IHC, and cellular proliferation by bromodeoxyuridine (BrdU) incorporation. It must be noted that the ERa antibody recognizes both mouse and human ERa, therefore ERa expression reflects total receptor expression. Figures 2B and C show scatter plots of ERa and PR levels, respectively, in non-Tsg and K303R ERa Tsg mice at varying ages. WT ERa mice were not included in further characterization studies because we did not observe any morphological differences between non-Tsg and WT ERa-expressing mice ( Figure 2A ). In addition, all untreated experiments were performed on intact animals, thus physiologic hormone levels were present in all animals. The data demonstrate that at 2 and 4 months of age, virgin mice have similar levels of ERa ( Figure 2B ) and PR ( Figure 2C ) expression. At 6 and 18 months of age, however, non-Tsg mice have much lower ERa ( Figure 2B , column 5) and PR ( Figure 2C , columns 5). In contrast, the K303R ERa mutant mice maintained a high level of ERa at both 6 months ( Figure 2B , columns 5 vs 6; P ¼ 0.017, Mann-Whitney) and 18 months of age ( Figure 2B , columns 7 vs 8; P ¼ 0.009, Mann-Whitney). For PR, the K303R ERa Tsg mice showed a similar pattern at 6 months ( Figure 2C , columns 5 vs 6; P ¼ 0.0647, Mann-Whitney) and 18 months ( Figure 2C , columns 7 vs 8; P ¼ 0.872, Mann-Whitney), though the differences were not statistically significant. Representative pictures of ERa and PR immunohistochemical staining of glands from 2-and 6-month-old virgins are shown in Figure 2D . Thus early ERa and PR expression was not different between non-Tsg and Tsg mice, but as the mice aged, Tsg mice maintained high levels of ERa, whereas the non-Tsg did not.
As we saw increased budding in the K303R ERa Tsg mice, we next analysed cellular proliferation. Figure 2D is a scatter plot of BrdU incorporation (in addition, 18-month-old animals were analysed for phospho-H1b, a surrogate marker of proliferation). However, the data did not reveal a significant difference in proliferation at any of the time-points analysed. As the structural differences were evident at 4 months, but not at 2 months of age, it is possible that the increased proliferation necessary to cause these phenotypic changes occurred at some point in between, and the 'burst' of activity was no longer present.
Pregnancy day 18 analyses
To evaluate potential differences in hormone responsiveness, we examined WT vs Tsg mice at day 18 of pregnancy. The mouse mammary gland undergoes a well-characterized functional differentiation process during pregnancy and lactation (for a complete review see Richert et al., 2000) . The initiation phase begins around midpregnancy and is associated with increased alveolar size, luminal expansion, cytoplasmic lipid droplet (CLD) synthesis and induction of milk protein gene expression. At parturition, progesterone declines, milk protein genes are transcriptionally upregulated, and secretory activity increases with release of both protein and CLDs into the lumen with lactation. To analyse the effects of hormone stimulation on the phenotype of Tsg mice, K303R ERa Tsg (n ¼ 5) and non-Tsg (n ¼ 4) mice were killed on pregnancy day 18, to examine mammary glands just before parturition. Whole mount analysis of these glands revealed that the mutant Tsg mice exhibited more fatpad filling when compared with non-Tsg mice (Figure 3 , panels a, b, d and e vs panels g, j, h and k). This increased fatpad filling was also associated with obviously increased alveolar budding (Figure 3, arrows) , and the development of very large dilated ducts (Figure 3, asterisks) . Dilated ducts were also verified using H&E staining of these glands and examined under low power (data not shown). Additionally, the proportion of alveoli to adipose tissue was much higher in the mutant Tsg animals as demonstrated by H&E stained sections (lowpower H&E's are not shown). Normally, the alveoli continue to expand filling more of the fatpad, thus, the proportion of alveoli to adipose tissue should continue to increase well into the secretion phase of lactation.
Higher magnification revealed that both non-Tsg (Figure 3 , panels c and f) and K303R Tsg (Figure 3 , panels i and l) mice had copious amounts of CLDs and secreted lipid droplets. Although there did not appear to be any differences in CLDs and secreted lipid droplets, the fatpads were almost completely filled in the Tsg mice, thus demonstrating that Tsg mice have lost or Figure 3 Increased alveolar budding in pregnant transgenic (Tsg) mice. Animals were killed at day 18 of pregnancy and the mammary glands analysed by whole mount and hematoxylin and eosin (H&E). Whole mounts of non-Tsg (panels a, b, d and e) and Tsg (panels g, h, j and k) mice. H&E of non-Tsg (panels c and f) and Tsg (panels i and l) mice. Single arrows (m) point to increased alveolar budding and asterisks show dilated ducts. Whole mount glands were stained with carmine alum and photographed at Â 10 and Â 50 magnification, whereas H&E stained slides were photographed at Â 1000 magnification (as indicated). Hormonal stimulation (E þ P) results in mammary gland hyperproliferation in K303R ERa-expressing mice Tsg mice displayed increased mammary epithelium following pregnancy. We next examined how chronic estrogen plus progesterone (E þ P) stimulation would affect the mammary gland. Beginning at 6 weeks of age, mice were subcutaneously implanted with E þ P tubing (Guzman et al., 1999) for 4-12 months and killed while on hormone treatment. Figure 4A shows representative micrographs of non-Tsg (panels a-h) and K303R ERa Tsg (panels i-p). Whole mount analyses demonstrated that 86% (6/7) of the Tsg mice had very large dilated distended ducts ( Figure 4A , asterisks) with copious alveolar structures ( Figure 4A , single arrows) that had filled the entire fatpad ( Figure 4A , panels i, j, m and n). In contrast, only 25% (2/8) of the non-Tsg animals have dilated ducts as shown in Figure 4A (panels a, b, e and f; P ¼ 0.04). These data show that K303R ERa Tsg mice may have an altered response to hormonal stimulation, an observation consistent with data in breast cancer cells in vitro (Fuqua et al., 2000) . Whole mounts of non-Tsg (panels a, b, e and f) and Tsg (panels i, j, m and n) mice; hematoxylin and eosin (H&E) of nonTsg (panels c and g) and Tsg (panels k and o) mice. Whole mount glands were stained with carmine alum and photographed at Â 10 and Â 50 magnification, H&E stained slides were photographed at Â 1000 magnification (as indicated). Panels d, h, l and p are representative pictures of casein stained glands photographed at Â 1000 magnification. Single arrows point to increased alveolar budding, asterisks show dilated ducts, double arrows show cytoplasmic lipid droplet (CLD) and cell filled lumens and arrowheads show milk fat globules (MFG). Quantitative real-time PCR was performed for b-casein (B) and p21 (C), relative quantization was performed setting the value obtained from one Tsg animal as the reference value.
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Examination of H&E-stained slides from chronically hormone-stimulated mice revealed differences in the stage of functional differentiation in WT vs mutant virgin Tsg mice. Mammary glands of non-Tsg mice exhibited small lumens with prominent CLDs (Figure 4A , panel c, double arrows) or cells still remaining in the alveolar lumen ( Figure 4A , panel f, double arrows). In contrast, mutant Tsg mice demonstrated CLDs and had significant milk fat globules (MFG) secreted into the lumens ( Figure 4A , panels k and o, arrowheads). Immunohistochemical analyses of these glands demonstrated the presence of b-casein ( Figure 4A , panels l and p), thus confirming the presence of milk within the glands of these mice, whereas mammary glands from non-Tsg mice only demonstrated small amounts of b-casein ( Figure 4A, panels d and h) . Additionally, we analysed b-casein mRNA as a marker of differentiation, and p21 mRNA as a marker of cellcycle activity. mRNA was purified from mammary glands of three non-Tsg and three Tsg mice and analysed by real-time quantitative RT-PCR. Scatter plots of these data show that K303R ERa-expressing mice have elevated levels of b-casein mRNA ( Figure 4B ) and reduced p21 mRNA levels ( Figure 4C ). These data suggest reduced cell-cycle controls and increased differentiation in mutant-expressing mice. Collectively, these data demonstrate an expedited maturation and differentiation phenotype in the K303R ERa Tsg mice.
Chronically, hormone-stimulated animals were also analysed for mammary gland ERa and PR expression, as well as cellular proliferation. It is known that estrogen treatment downregulates ERa levels (Borras et al., 1994) , so it was not surprising that chronic (4-12 months) hormone treatment led to a complete downregulation of ERa in all animals (data not shown). Additionally, PR expression was low in both non-Tsg and Tsg animals. The percentage of proliferating epithelial cells, as measured by phospho-H1b staining, was also low with no observable differences noted between groups. Although these data did not demonstrate any statistical differences in ERa, PR or proliferation following chronic stimulation, it does suggest that important physiologic hormonal regulation of ERa remains intact.
MMTV-Her/neu2 X K303R ERa bigenic mice
Early pregnancy in humans is known to protect against breast cancer development ( Russo and Russo, 2004) . Pregnancy and hormonal stimulation both expedited maturation in K303R ERa mutant Tsg mice resulting in increased mammary structures and differentiation. We therefore wanted to determine if the mutation would provide protection against tumorigenesis. The HER2/ neu-strain of mice (Guy et al., 1992) were thus mated to our K303R-ERa, WT ERa and non-Tsg litter mates. Progeny were followed until first tumor formation, and the results are plotted in Figure 5a . Mice expressing only the neu transgene in the FVB/C57Bl6 background developed tumors with a mean latency of 9.5 months. WT ERa/neu Tsg mice developed tumors with a mean latency of 9 months, which was not statistically different. In contrast, K303R ERa mutant/neu mice exhibited a median time to tumorigenesis of 11.8 months, which was statistically longer than either the WT ERa/neu Tsg or the neu Tsg animals (w 2 ¼ 0.0007). We also found that ERa expression was low-toundetectable in all tumors (data not shown), consistent with previous analyses of HER2/neu-mediated tumors (Bershtein et al., 2003) . Additionally, HER2/neu expression was analysed by immunohistochemistry (IHC), with the majority of tumors expressing, and the percentages of cells expressing were not different between the groups.
Another established method of mammary gland tumorigenesis is the 7,12-dimethylbenzanthracene (DMBA) chemical carcinogen-induced model (Medina, 1974) . In contrast with our neu results, when mammary tumorigenesis was induced with DMBA carcinogen, there were no differences in time to tumor formation or K303R ERa alters mammary development and tumorigenesis MH Herynk et al tumor incidence in either K303R ERa mutant Tsg animals or non-Tsg (Figure 5b) . We conclude that the K303R ERa mutation may delay HER2/neu-mediated tumorigenesis, perhaps through the observed early differentiation of the gland.
Discussion
Human mammary gland development is a complex process involving ductal elongation, ductal branching, progressive alveolar lobule formation and multiple stages or rounds of glandular differentiation (Russo and Russo, 2004) . With the onset of puberty, rudimentary mammae begin to grow giving rise to ducts and lobules. Terminal end buds grow invasively until the end of the fatpad is reached. These growing end buds give rise to an expanding network of branching ducts, terminal ducts and alveolar buds. Terminal ducts and alveolar buds make up the lobules, which progressively mature into differentiated glands (Russo and Russo, 2004) .
In this article, we demonstrate an increased incidence of alveolar budding in 4-month-old K303R ERa Tsg mice, but not in the WT ERa Tsg or non-Tsg littermates. Although our K303R ERa-expressing mice demonstrated precocious alveolar budding, we did not observe hyperplastic growth in any of the animals. In contrast, Frech et al. (2005) have demonstrated a high incidence of abnormal mammary structures by 4 months of age in Tsg mice overexpressing WT ERa. It is doubtful that differences between our mice and their findings are due to strain differences, because both studies used the C57/Bl6 strain. However, analysis of ERa levels demonstrated that our K303R ERa Tsg and non-Tsg mice had similar levels of ERa protein expression under physiologic estrogen concentrations. Furthermore, ERa expression was completely downregulated when the animals were treated with exogenous E þ P, demonstrating that the K303R ERa mutant animals maintained normal posttranscriptional, hormone-induced downregulation of ER. It is important to note that the Tsg animals described by Frech et al. (2005) had a twofold increased level of ERa, and that ERa was not completely downregulated following exogenous hormonal stimulation. This loss of physiologic ERa regulation may contribute to the phenotypic differences observed between our WT ERa Tsg mice and their model. These phenotypic differences following the chronic stimulation of ERa demonstrate a potential role for aberrant ERa signaling in the development of breast hyperplasias and cancer.
Although we observed no differences in ERa expression at early ages, there was a striking phenotypic difference at 4 months of age in the mutant mice. Thus these differences we report here were not due to an increased amount of ERa protein, but may have been caused by an increase in signaling due to increased activity of the K303R mutant receptor. This is supported by our previous in vitro data demonstrating hypersensitivity to estrogen (Fuqua et al., 2000) , altered interactions with cofactors (Fuqua et al., 2000; Cui et al., 2006) and altered posttranslational regulation of the K303R ERa mutant protein in breast cancer cells (Cui et al., 2004) .
We have observed many structural and molecular features demonstrating expedited differentiation in these K303R ERa-expressing mice. First, 4-month-old virgin mice demonstrated increased alveolar budding compared with non-Tsg mice. However, both mice cohorts had similar levels of budding at later time-points suggesting an increased rate of mammary gland differentiation in K303R ERa-expressing virgin mice. To further analyse this observed expedited differentiation, mammary glands from pregnant mice and mice treated with chronic hormonal stimulation were analysed. Pregnant K303R ERa-expressing mice had increased filling of the fatpad, increased alveolar budding and elevated levels of large dilated ducts when compared with non-Tsg mice. These structural differences correlate with more advanced stages of lactation normally seen following parturition. Although we saw significant structural differences we did not observe any differences in CLDs and MFGs. These mice were killed toward the end of the normal gestation period and close to parturition, thus examination of CLDs and MFGs at an earlier time-point may reveal differences in lipid secretions. Similar to the results observed in pregnant mice, chronic hormonal stimulation of K303R ERa-expressing mice also resulted in increased fatpad filling, more alveolar structures and large dilated ducts when compared with non-Tsg mice. Chronic hormonal stimulation also resulted in increased MFGs released into the alveolar lumens of Tsg mice. In comparison, non-Tsg mice demonstrated small lumens with a cellular component and minimal MFGs. The mouse mammary gland has been shown to go through a defined pattern of growth and differentiation; here we show that K303R ERa-expressing mice complete this process in an accelerated manner compared with non-Tsg littermates.
Many epidemiologic studies have reported a protective effect of parity on mammary carcinogenesis (Cullinane et al., 2005) , and indeed these studies have been confirmed in laboratory settings. Exogenous hormonal administration can mimic the protection afforded by full-term pregnancy against chemical carcinogens such as DMBA or MNU (Guzman et al., 1999; Medina, 2004) . Additionally, it has been shown that this protective effect may be p53 dependent (Medina, 2004) . In addition to breast cancer, Tilli et al. (2003) have reported that ERa overexpression reduced the incidence of lymphomas, but not salivary tumors in Simian virus 40 large T-antigen mice. Although much emphasis has been placed on the role of ERa in breast tumorigenesis, the evidence clearly indicates that there is a still undefined role for the receptor in delaying and/or altering tumorigenesis.
The delay in HER2/neu-mediated tumor formation, but not DMBA carcinogen-induced tumorigenesis is intriguing, and suggests that K303R mutant ERa function may oppose the oncogenic actions of HER2, but probably not ras-mediated tumorigenesis (DMBA). Mammary tumors induced by the HER2/neu oncogene are almost exclusively ER-negative, supporting opposing roles for HER2/neu and estrogen. Isoflavonecontaining diets rich in phytoestrogens increased the latency period of Her2/neu driven mammary tumorigenesis (Jin and MacDonald, 2002) , and short-term exogenous estrogen exposure or E þ P supplementation significantly delayed tumorigenesis of MMTV-neu/ ErbB2 Tsg mice (Rajkumar et al., 2007) . In contrast, Yang et al. (2003) have reported that the exogenous administration of high-dose estrogen reduced the latency period of HER2/neu-mediated mammary tumorigenesis. These investigators utilized a single highdose estrogen pellet, and circulating estrogen gradually tapered off over during the course of the 8 weeks of treatment (Yang et al., 2003) . In comparison, the isoflavone diet would lead to a sustained low-dose of phytoestrogens, and in the Rajkumar et al. (2007) study hormone stimulation occurred over a 3-week period, and was abruptly ended by hormone removal, which could account for the differences in outcomes. One additional study using double Tsg mice expressing the aromatase gene and the HER2/neu gene in mammary glands led to a significant reduction in tumor incidence (Tekmal et al., 2007) . The authors went on to demonstrate reduced cyclin D1 and phosphorylated RB in bigenic mice, thereby suggesting the reduced mammary tumor incidence may be due to reduced cellcycle activity (Tekmal et al., 2007) . These results demonstrate that hormone treatments can significantly delay mammary tumorigenesis driven by HER2/neu, although this may occur in a treatment-specific manner. Our bitransgenic studies herein utilized a pituitary isograft to provide continual high-dose hormonal stimulation. We observed increased latency of HER2/ neu driven tumorigenesis in K303R ERa-expressing mice, but not in HER2/neu X WT ERa bitransgenic model animals. These data suggest that high levels of hormones alone are not sufficient to delay tumorigenesis, and altered signaling in the K303R ERa mutant, while leading to expedited growth, also provided a protective mechanism against HER2/neu-mediated tumorigenesis, potentially through accelerated differentiation of the mammary gland. Precocious mammary gland development and differentiation in the K303R mutant mice likely provided a measure of 'protection' against the oncogenic insult from the HER2/neu oncogene.
In summary, our data demonstrate an important role for the K303R ERa mutant in the maturation and differentiation of the mouse mammary gland. Although mammary glands in animals expressing WT ERa showed a phenotypically normal appearance, K303R ERa-expressing animals exhibited advanced alveolar budding, extensively dilated ducts and expedited differentiation in response to hormonal stimulation. Additionally, the K303R ERa Tsg mice were delayed in HER2/neu-mediated, but not DMBA carcinogen-induced tumorigenesis. Whether this 'protective' effect is limited to HER2-mediated tumorigenesis or will provide general protection from various insults including multiple oncogenes remains to be determined.
Materials and methods
Animal care and necropsy Animals were housed and maintained in accordance with the animal care regulations of Baylor College of Medicine. All of the animal experiments were approved by the Baylor College of Medicine Animal Care and Use Committee pursuant to NIH guidelines. Mice were injected with BrdU (Amersham, Piscataway, NJ, USA) 2 h before euthanasia and necropsy. All procedures were performed while the animals were anesthetized with isoflurane (Abbott Laboratories, North Chicago, IL, USA).
Generation of MMTV-HA-tagged K303R ERa transgenic mice We previously described the cloning and development of the pcDNA1-K303R ERa expression vector (Fuqua et al., 2000) . EcoR1 DNA fragments (1.8 kb) encoding an HA-tagged K303R or HA-WT ERa were subcloned into the pBSpKCR3 vector at the EcoR1 restriction site, thereby placing the cDNA under the control of the MMTV promoter for selective expression in mammary epithelium. These vectors were used to generate Tsg mice by pronuclear injection of C57Bl6 founder mice in the Baylor college of Medicine Genetically Engineered Mouse core (Dr Francesco Demayo, Director). Ten founder lines of each transgene were identified by Southern blot analysis. The presence of the transgene was identified in subsequent offspring by genomic PCR analysis of tail DNA. Briefly, PCR primers were synthesized, which were specific for the HA-tagged human ERa transgene only. Endogenous mouse ERa did not amplify with these primers (not shown). The forward primer to the HA sequence was 5 0 -GAATTCATGGCTTACCCCTACG-3 0 , and the reverse primer to the human ERa sequence was 5 0 -CGGAATTCTG CAGTAGCATCAGCGGGCT-5 0 , which amplified a 345 bp band from the human transgene. TSH-b was used as a positive control for the PCR as described (Lavrovsky et al., 1998) . PCR conditions were as follows: 95 1C for 2 min À1 cycle, 95 1C for 1 min melting, 60 1C for 40 s annealing, 72 1C extension for 35 cycles and 72 1C for 7 min À1 cycle. PCR products were separated on 5% acrylamide gels, and analysed by ethidium bromide staining.
Reverse transcription polymerase chain reaction and SNaPshot analysis to confirm the mutation Total RNA was purified from snap frozen mammary glands using the EZ1 Robot and the Universal RNA kit (Qiagen, Valencia, CA, USA) according to the manufacturer. Total RNA (50 mg) was reverse transcribed using M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer. PCR and SNaPshot mutation analyses have been previously described (Herynk et al., 2007) . Briefly, PCR was performed with an initial denaturation step of 95 1C for 10 min followed by an additional 35 cycles of denaturation, annealing and extension. Unincorporated primers were removed with the addition of exonuclease I (US Biochemical, Cleveland, OH, USA) and shrimp alkaline phosphatase (Roche Applied Bioscience, Basel, Switzerland). SNaPshot analysis was performed using BigDye-labeled terminator automated fluorescent sequencing with an ABI PRISM BigDye Terminator cycle sequencing ready reaction kit with AmpliTaq DNA polymerase (Perkin-Elmer/Applied
